Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

UPDATE 2-British mid-caps advance as Brexit talks continue

Published 12/14/2020, 05:30 PM
Updated 12/15/2020, 01:00 AM
© Reuters.

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
* AstraZeneca shares fall on $39-billion Alexion bill
* Codemasters shine on acquisition deal
* FTSE 100 down 0.23%, FTSE 250 adds 0.72%

(Updates to market close)
By Medha Singh and Shivani Kumaresan
Dec 14 (Reuters) - London's mid-cap stocks climbed on Monday
on bets that a Brexit trade deal between Britain and the
European Union was still possible, while drugmaker AstraZeneca
slid on a $39 billion buyout of U.S.-based Alexion
Pharmaceuticals.
The domestically focussed FTSE 250 .FTMC , considered a
barometer for Brexit sentiment, closed about 0.7% higher
although it was off its session highs with financial and
consumer discretionary stocks providing the biggest boost.
A strong pound took the shine off of the exporter-heavy FTSE
100 .FTSE , down 0.2% as London and Brussels agreed to "go the
extra mile" in coming days to try to reach an elusive trade
agreement. GBP/
"With the vaccine roll-out set to produce a marked pick-up
in growth from the second quarter onwards, markets should remain
well supported despite any worries over the deteriorating near
term outlook," said Rupert Thompson, chief investment officer at
Kingswood.
London's stock indexes have tracked a rally in global equity
markets as signs of working COVID-19 vaccines raised hopes of a
faster economic rebound next year. But gains have been capped by
fears around the near-term economic damage from business curbs
and mass layoffs.
London will move into England's highest tier of COVID-19
restrictions to fight an exponential rise in infection rates,
the government said. On Monday, Britain's trade body for manufacturing slashed
its 2021 growth forecast for the sector. In company news, AstraZeneca shares AZN.L sank 5.7% as
investors moved to price in the drugmaker's $39 billion deal for
biotech firm Alexion ALXN.O , one of this year's biggest
mergers globally. Codemasters CDM.L soared 22.4% after Electronic Arts
EA.O said it would buy the video game developer in a deal
worth $1.2 billion, trumping an earlier agreement between the
British company and rival Take-Two Interactive Software.
TTWO.O

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.